Trail Ridge Investment Advisors LLC Makes New Investment in United Therapeutics Co. (NASDAQ:UTHR)

Trail Ridge Investment Advisors LLC acquired a new position in United Therapeutics Co. (NASDAQ:UTHR) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,120 shares of the biotechnology company’s stock, valued at approximately $251,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Machina Capital S.A.S. acquired a new position in United Therapeutics in the first quarter worth $45,000. Neo Ivy Capital Management acquired a new position in United Therapeutics in the second quarter worth $48,000. Global Retirement Partners LLC boosted its stake in United Therapeutics by 198.7% in the first quarter. Global Retirement Partners LLC now owns 224 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 149 shares in the last quarter. Atlas Capital Advisors LLC acquired a new position in United Therapeutics in the fourth quarter worth $51,000. Finally, Archer Investment Corp bought a new stake in shares of United Therapeutics during the first quarter worth $52,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In related news, EVP Paul A. Mahon sold 6,000 shares of the stock in a transaction that occurred on Thursday, July 6th. The stock was sold at an average price of $215.19, for a total transaction of $1,291,140.00. Following the completion of the transaction, the executive vice president now directly owns 36,599 shares of the company’s stock, valued at $7,875,738.81. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, EVP Paul A. Mahon sold 2,500 shares of the firm’s stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $243.87, for a total value of $609,675.00. Following the completion of the sale, the executive vice president now directly owns 36,599 shares of the company’s stock, valued at $8,925,398.13. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Paul A. Mahon sold 6,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 6th. The shares were sold at an average price of $215.19, for a total value of $1,291,140.00. Following the completion of the sale, the executive vice president now directly owns 36,599 shares of the company’s stock, valued at $7,875,738.81. The disclosure for this sale can be found here. Insiders sold 20,500 shares of company stock valued at $4,684,935 over the last three months. Company insiders own 12.50% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on UTHR shares. LADENBURG THALM/SH SH boosted their target price on United Therapeutics from $256.00 to $268.00 and gave the stock a “buy” rating in a research report on Thursday, August 3rd. StockNews.com started coverage on United Therapeutics in a research report on Thursday, August 17th. They set a “buy” rating for the company. HC Wainwright restated a “buy” rating and set a $300.00 target price on shares of United Therapeutics in a research report on Thursday, August 3rd. Morgan Stanley boosted their target price on United Therapeutics from $316.00 to $318.00 and gave the stock an “overweight” rating in a research report on Thursday, August 3rd. Finally, Wedbush upped their price objective on United Therapeutics from $305.00 to $307.00 and gave the company an “outperform” rating in a report on Thursday, August 3rd. Two analysts have rated the stock with a sell rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $296.44.

United Therapeutics Stock Down 0.2 %

Shares of UTHR stock traded down $0.37 on Friday, hitting $222.26. 25,665 shares of the stock were exchanged, compared to its average volume of 433,018. The company has a current ratio of 8.68, a quick ratio of 8.40 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $10.43 billion, a P/E ratio of 12.59 and a beta of 0.62. The business has a 50-day moving average of $232.00 and a 200 day moving average of $227.22. United Therapeutics Co. has a fifty-two week low of $201.65 and a fifty-two week high of $283.09.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported $5.24 earnings per share for the quarter, topping the consensus estimate of $4.57 by $0.67. The company had revenue of $596.50 million during the quarter, compared to analysts’ expectations of $524.18 million. United Therapeutics had a return on equity of 17.52% and a net margin of 41.29%. United Therapeutics’s revenue for the quarter was up 27.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.41 earnings per share. Equities analysts anticipate that United Therapeutics Co. will post 18.95 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.